* Have suggestions for future podcast guests (or other feedback)? Let us know here!
* Want to write with us? Send a pitch using this form :)
In episode 46 of The Gradient Podcast, Daniel Bashir speaks to Luis Voloch.
Luis is co-founder of Immunai, a leading AI-led drug discovery company with over 140 employees and over one billion dollar valuation based out of NYC & Tel Aviv. Before Immunai, Luis was Head of Data Science and Machine Learning at ITC and worked at Palantir, where he worked on a variety of ML efforts. He did his studies and research in Math and CS in MIT.
He has also led AI, genomics, and software efforts at a number of other companies.
Subscribe to The Gradient Podcast: Apple Podcasts | Spotify | Pocket Casts | RSSFollow The Gradient on Twitter
Outline:
* (00:00) Intro
* (02:25) Luis’s math background and getting into AI
* (06:35) Luis’s PhD experience, proving theoretical guarantees for recommendation systems
* (09:45) Why Luis left his PhD
* (15:45) Why Luis is excited about intersection of ML and biology
* (18:28) Challenges of applying AI to biology
* (22:55) Immunai
* (27:03) Challenges in building a biotech (or “tech-bio”) company
* (30:30) Research at Immunai, Neural Design for Genetic Perturbation Experiments
* (34:43) Interpretability in ML + biology
* (36:00) What Luis plans to do next
* (37:55) Luis’s advice for grad students / ML people interested in biology
* (40:00) Luis’s perspective on the future of AI + biology
* (43:10) Outro
Links:
* Luis on LinkedIn, Crunchbase
* Luis’s article on The convergence of deep neural networks and immunotherapy
* Papers
* Neural Design for Genetic Perturbation Experiments